SEC Filing Summary: Predictive Oncology Inc. (POAI)
Business Context and Reporting Period
This Form 8-K Current Report, dated November 20, 2025, addresses a material event regarding Predictive Oncology Inc.'s compliance with Nasdaq listing requirements. The filing specifically concerns the resolution of a deficiency in the minimum stockholders' equity requirement (Nasdaq Listing Rule 5550(b)(1)) previously notified by The Nasdaq Stock Market LLC on November 20, 2024.
Key Financial Metrics
- Capital Raised: Approximately $343.5 million aggregate value from two private investment in public equity (PIPE) transactions closed on October 7, 2025.
- Cash Proceeds: Approximately $50.8 million in cash.
- In-Kind Contributions: Approximately $292.7 million in notional value of crypto assets, representing a discounted value of approximately $173.3 million.
- Stockholders' Equity: Exceeds $2.5 million as of the filing date.
- Revenue, Profit, and Cash Flow: The filing text does not provide specific values for revenue, net income, operating cash flow, or debt levels.
Material Changes
The primary material change is the restoration of compliance with Nasdaq listing standards. Following the October 2025 PIPE transactions, the Company's stockholders' equity increased to over $2.5 million, resolving the deficiency that had been outstanding since late 2024.
Outlook, Risks, and Management Commentary
Management states that the Company believes it has regained compliance with the Stockholders' Equity Requirement. The filing does not provide forward-looking guidance, updated risk factors, or commentary on future operational performance beyond the resolution of the listing status.
Investor Verification Checklist
- Verify the valuation methodology and fair value assessment of the $292.7 million in-kind crypto asset contributions.
- Confirm the current trading status of POAI on the Nasdaq Capital Market following this compliance notice.
- Review the terms of the PIPE transactions to understand investor rights and potential dilution.
- Check subsequent filings for any updated financial statements reflecting the new equity capital.